| Type of support |
Approvals 2001-2022 (US$)(29 May 2018) |
Commitments 2001-2022 (US$)(29 May 2018) |
Disbursements 2000-2018 (US$)(29 May 2018) |
% Disbursed(29 May 2018) |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
|---|
|
| Total |
$210,061,210 |
$254,172,210 |
$204,462,878 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Support (CASHSUPP) |
$145,000 |
$170,000 |
$145,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$4,978,500 |
$4,978,500 |
$4,978,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 2) |
$4,436,347 |
$4,436,347 |
$4,436,347 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 3) |
$5,040,000 |
$11,760,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV Demo (NVS) |
$189,506 |
$189,506 |
$190,622 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$9,705,605 |
$9,705,605 |
$9,705,605 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$628,479 |
$1,192,479 |
$746,203 |
119% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$931,560 |
$931,560 |
$931,560 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$757,679 |
$757,679 |
$343,829 |
45% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles (NVS) |
$1,218,229 |
$1,218,229 |
$910,729 |
75% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles-Rubella (NVS) |
$6,000,965 |
$6,000,965 |
$6,000,965 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A (NVS) |
$960,871 |
$1,839,371 |
$1,013,958 |
106% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - mini catch-up campaign (NVS) |
$3,134,671 |
$3,134,671 |
$3,134,671 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - mini catch-up op.costs (OPC) |
$2,571,802 |
$2,571,802 |
$2,571,802 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR - Operational costs (OPC) |
$4,925,847 |
$4,925,847 |
$4,925,847 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$63,816,939 |
$66,348,439 |
$64,389,968 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$54,151,163 |
$71,524,663 |
$56,157,143 |
104% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Product Switch Grant (PSG) |
$194,286 |
$194,286 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$42,715,267 |
$58,733,767 |
$40,321,635 |
94% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$3,558,494 |
$3,558,494 |
$3,558,494 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format